<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>Diabetes Readmission Prediction - EDA Documentation</title>
    <style>
        body {
            font-family: 'Segoe UI', Tahoma, Geneva, Verdana, sans-serif;
            line-height: 1.6;
            margin: 0;
            padding: 20px;
            background-color: #f8f9fa;
            color: #333;
        }
        .container {
            max-width: 1200px;
            margin: 0 auto;
            background-color: white;
            padding: 40px;
            border-radius: 10px;
            box-shadow: 0 0 20px rgba(0,0,0,0.1);
        }
        h1 {
            color: #2c3e50;
            text-align: center;
            border-bottom: 3px solid #3498db;
            padding-bottom: 20px;
            margin-bottom: 30px;
        }
        h2 {
            color: #34495e;
            border-left: 4px solid #3498db;
            padding-left: 15px;
            margin-top: 40px;
        }
        h3 {
            color: #2c3e50;
            margin-top: 25px;
        }
        .highlight {
            background-color: #e8f4fd;
            padding: 15px;
            border-radius: 5px;
            border-left: 4px solid #3498db;
            margin: 20px 0;
        }
        .success {
            background-color: #d4edda;
            padding: 15px;
            border-radius: 5px;
            border-left: 4px solid #28a745;
            margin: 20px 0;
        }
        .warning {
            background-color: #fff3cd;
            padding: 15px;
            border-radius: 5px;
            border-left: 4px solid #ffc107;
            margin: 20px 0;
        }
        .info-box {
            background-color: #f8f9fa;
            border: 1px solid #dee2e6;
            border-radius: 5px;
            padding: 20px;
            margin: 20px 0;
        }
        .metric {
            display: inline-block;
            background-color: #3498db;
            color: white;
            padding: 8px 15px;
            border-radius: 20px;
            margin: 5px;
            font-weight: bold;
        }
        .metric.success {
            background-color: #28a745;
        }
        .metric.warning {
            background-color: #ffc107;
            color: #333;
        }
        .metric.danger {
            background-color: #dc3545;
        }
        table {
            width: 100%;
            border-collapse: collapse;
            margin: 20px 0;
        }
        th, td {
            border: 1px solid #dee2e6;
            padding: 12px;
            text-align: left;
        }
        th {
            background-color: #f8f9fa;
            font-weight: bold;
        }
        .footer {
            text-align: center;
            margin-top: 40px;
            padding-top: 20px;
            border-top: 1px solid #dee2e6;
            color: #6c757d;
        }
        @media print {
            body { background-color: white; }
            .container { box-shadow: none; }
            .highlight, .success, .warning { break-inside: avoid; }
        }
    </style>
</head>
<body>
    <div class="container">
        <h1>üè• Diabetes Readmission Prediction - EDA Documentation</h1>

        <div class="info-box">
            <strong>Project:</strong> Healthcare AI Project: Diabetic Readmission Prediction<br>
            <strong>Phase:</strong> Exploratory Data Analysis (EDA) - Phase 1.2<br>
            <strong>Date:</strong> August 2025<br>
            <strong>Dataset:</strong> UCI Diabetes Dataset (101,766 records, 50+ features)<br>
            <strong>Author:</strong> Mohammad Javad Aghababaie Beni
        </div>

        <h2>üìã Executive Summary</h2>
        <p>This document provides a comprehensive analysis of the Exploratory Data Analysis (EDA) phase completed for the Diabetes Readmission Prediction project. The EDA process has successfully transformed raw healthcare data into actionable insights, creating a solid foundation for feature engineering and machine learning modeling.</p>

        <div class="success">
            <h3>‚úÖ Key Achievements</h3>
            <ul>
                <li><strong>Comprehensive Data Understanding:</strong> Analyzed 101,766 patient records with 50+ features</li>
                <li><strong>Target Variable Creation:</strong> Established binary classification for 30-day readmission prediction</li>
                <li><strong>Clinical Risk Stratification:</strong> Created healthcare-specific risk categories</li>
                <li><strong>Advanced Feature Engineering:</strong> Developed 8 new clinical features</li>
                <li><strong>Socioeconomic Analysis:</strong> Integrated social determinants of health</li>
                <li><strong>Production-Ready Insights:</strong> Clear roadmap for Week 2 modeling phase</li>
            </ul>
        </div>

        <h2>üéØ Project Overview</h2>
        <h3>Objective</h3>
        <p>Build an end-to-end ML system to predict 30-day readmission risk for diabetic patients using MLOps best practices and healthcare-specific insights.</p>

        <h3>Dataset Characteristics</h3>
        <ul>
            <li><strong>Size:</strong> 101,766 patient encounters</li>
            <li><strong>Features:</strong> 50+ clinical and demographic variables</li>
            <li><strong>Time Period:</strong> 1999-2008 (10 years of clinical care)</li>
            <li><strong>Source:</strong> 130 US hospitals and integrated delivery networks</li>
            <li><strong>Target:</strong> Binary classification (readmission within 30 days: Yes/No)</li>
        </ul>

        <h2>üîç EDA Process & Findings</h2>

        <h3>Phase 1: Data Overview & Quality Assessment</h3>

        <h4>1.1 Dataset Dimensions & Structure</h4>
        <ul>
            <li><strong>Total Records:</strong> 101,766 patient encounters</li>
            <li><strong>Total Features:</strong> 50 columns</li>
            <li><strong>Data Types:</strong> 37 categorical (object), 13 numerical (int64)</li>
            <li><strong>Memory Usage:</strong> Optimized for large-scale analysis</li>
        </ul>

        <h4>1.2 Missing Value Analysis</h4>
        <div class="warning">
            <strong>Critical Findings:</strong>
            <ul>
                <li><strong>max_glu_serum:</strong> 94.7% missing (96,420 records)</li>
                <li><strong>A1Cresult:</strong> 83.3% missing (84,748 records)</li>
            </ul>
        </div>

        <h4>1.3 Data Type Validation</h4>
        <div class="success">
            <strong>Key Insights:</strong>
            <ul>
                <li>‚úÖ No mixed data types detected</li>
                <li>‚ö†Ô∏è High cardinality categorical variables identified:
                    <ul>
                        <li><code>diag_1</code>: 717 unique values</li>
                        <li><code>diag_2</code>: 749 unique values</li>
                        <li><code>diag_3</code>: 790 unique values</li>
                        <li><code>medical_specialty</code>: 73 unique values</li>
                    </ul>
                </li>
            </ul>
        </div>

        <h3>Phase 2: Target Variable Analysis</h3>

        <h4>2.1 Target Variable Creation</h4>
        <div class="highlight">
            <strong>Binary Classification Established:</strong>
            <ul>
                <li><span class="metric success">0 (No Readmission): 90,409 patients (88.84%)</span></li>
                <li><span class="metric danger">1 (Readmission <30 days): 11,357 patients (11.16%)</span></li>
            </ul>
        </div>

        <h3>Phase 3: Clinical Risk Stratification</h3>

        <h4>3.1 Risk Categories Created</h4>
        <table>
            <thead>
                <tr>
                    <th>Risk Category</th>
                    <th>Diagnosis Range</th>
                    <th>Patient Count</th>
                    <th>Percentage</th>
                </tr>
            </thead>
            <tbody>
                <tr>
                    <td><span class="metric success">Low Risk</span></td>
                    <td>1-3 diagnoses</td>
                    <td>4,077</td>
                    <td>4.0%</td>
                </tr>
                <tr>
                    <td><span class="metric warning">Medium Risk</span></td>
                    <td>4-6 diagnoses</td>
                    <td>27,091</td>
                    <td>26.6%</td>
                </tr>
                <tr>
                    <td><span class="metric danger">High Risk</span></td>
                    <td>7-10 diagnoses</td>
                    <td>70,500</td>
                    <td>69.3%</td>
                </tr>
                <tr>
                    <td><span class="metric danger">Critical Risk</span></td>
                    <td>11+ diagnoses</td>
                    <td>98</td>
                    <td>0.1%</td>
                </tr>
            </tbody>
        </table>

        <h4>3.2 Readmission Rates by Risk Category</h4>
        <table>
            <thead>
                <tr>
                    <th>Risk Category</th>
                    <th>Readmission Rate</th>
                    <th>Clinical Significance</th>
                </tr>
            </thead>
            <tbody>
                <tr>
                    <td>Low Risk</td>
                    <td><span class="metric success">6.97%</span></td>
                    <td>Minimal intervention needed</td>
                </tr>
                <tr>
                    <td>Medium Risk</td>
                    <td><span class="metric warning">9.44%</span></td>
                    <td>Standard monitoring</td>
                </tr>
                <tr>
                    <td>High Risk</td>
                    <td><span class="metric danger">12.06%</span></td>
                    <td>Enhanced monitoring required</td>
                </tr>
                <tr>
                    <td>Critical Risk</td>
                    <td><span class="metric danger">14.29%</span></td>
                    <td>Intensive intervention needed</td>
                </tr>
            </tbody>
        </table>

        <h3>Phase 4: Treatment Complexity Analysis</h3>

        <h4>4.1 Complexity Score Creation</h4>
        <div class="highlight">
            <strong>Composite Score Formula:</strong><br>
            <code>Treatment Complexity = (Procedures √ó 0.3) + (Medications √ó 0.4) + (Diagnoses √ó 0.3)</code>
        </div>

        <h4>4.2 Complexity Categories</h4>
        <table>
            <thead>
                <tr>
                    <th>Complexity Level</th>
                    <th>Patient Count</th>
                    <th>Readmission Rate</th>
                    <th>Clinical Action</th>
                </tr>
            </thead>
            <tbody>
                <tr>
                    <td>Low</td>
                    <td>372 (0.4%)</td>
                    <td><span class="metric success">4.03%</span></td>
                    <td>Standard care</td>
                </tr>
                <tr>
                    <td>Medium</td>
                    <td>4,690 (4.6%)</td>
                    <td><span class="metric warning">7.55%</span></td>
                    <td>Enhanced monitoring</td>
                </tr>
                <tr>
                    <td>High</td>
                    <td>14,705 (14.5%)</td>
                    <td><span class="metric warning">9.17%</span></td>
                    <td>Care coordination</td>
                </tr>
                <tr>
                    <td>Critical</td>
                    <td>80,671 (79.3%)</td>
                    <td><span class="metric danger">11.77%</span></td>
                    <td>Intensive management</td>
                </tr>
            </tbody>
        </table>

        <h3>Phase 5: Socioeconomic Analysis</h3>

        <h4>5.1 Risk Score Creation</h4>
        <div class="highlight">
            <strong>Scoring System:</strong>
            <ul>
                <li><strong>Medicaid (MC):</strong> +2 points (higher risk)</li>
                <li><strong>Medicare (MD):</strong> +1 point</li>
                <li><strong>African American Race:</strong> +1 point</li>
                <li><strong>Unknown Age/Weight:</strong> +1 point each</li>
            </ul>
        </div>

        <h3>Phase 6: Advanced Feature Engineering</h3>

        <h4>6.1 New Clinical Features Created</h4>
        <div class="success">
            <strong>8 Advanced Features Developed:</strong>
            <ol>
                <li><strong>Medication Adherence Score</strong> - Mean: 1.94, Range: 0-5</li>
                <li><strong>Hospital Utilization Score</strong> - Mean: 0.38</li>
                <li><strong>Lab Efficiency Score</strong> - Mean: 9.77</li>
                <li><strong>Age Group Categorization</strong> - Young, Middle, Senior, Elderly</li>
                <li><strong>Length of Stay Risk</strong> - Low, Medium, High, Critical</li>
                <li><strong>Diagnosis Complexity</strong> - Mean: 0.08</li>
                <li><strong>Insurance-Age Interaction</strong> - Combined risk factor analysis</li>
                <li><strong>Clinical Severity Index</strong> - Mean: 7.02</li>
            </ol>
        </div>

        <h2>üí° Why These EDA Steps Were Essential</h2>

        <h3>1. Healthcare Domain Expertise</h3>
        <ul>
            <li><strong>Risk Stratification:</strong> Standard practice in healthcare</li>
            <li><strong>Treatment Complexity:</strong> Directly impacts outcomes</li>
            <li><strong>Socioeconomic Factors:</strong> Social determinants of health</li>
            <li><strong>Age Group Analysis:</strong> Age-related risk patterns</li>
        </ul>

        <h3>2. Machine Learning Optimization</h3>
        <ul>
            <li><strong>Feature Engineering Foundation:</strong> Created clinically relevant predictors</li>
            <li><strong>Data Quality:</strong> Ensured modeling data integrity</li>
            <li><strong>Clinical Metrics:</strong> Domain-specific performance measures</li>
        </ul>

        <h3>3. Production Readiness</h3>
        <ul>
            <li><strong>MLOps Integration:</strong> Feature pipeline and monitoring requirements defined</li>
            <li><strong>Business Impact:</strong> Cost analysis and ROI calculation framework</li>
            <li><strong>Clinical Integration:</strong> Workflow and decision support requirements</li>
        </ul>

        <h2>üöÄ How EDA Supports Next Steps</h2>

        <h3>Week 2: Feature Engineering & Modeling</h3>
        <div class="info-box">
            <strong>Immediate Actions:</strong>
            <ol>
                <li><strong>Feature Selection:</strong> Choose top 20-30 features from 58+ available</li>
                <li><strong>Data Preprocessing:</strong> Handle missing values and encode categorical variables</li>
                <li><strong>Baseline Models:</strong> Train Logistic Regression, Random Forest, XGBoost</li>
                <li><strong>Performance Evaluation:</strong> Healthcare-specific metrics and validation</li>
            </ol>
        </div>

        <h2>üìä Key Insights for Stakeholders</h2>

        <h3>Clinical Teams</h3>
        <ul>
            <li><strong>Risk Stratification:</strong> Clear patient categorization for care planning</li>
            <li><strong>Treatment Complexity:</strong> Resource allocation guidance</li>
            <li><strong>Readmission Prevention:</strong> High-risk patient identification</li>
            <li><strong>Clinical Decision Support:</strong> Data-driven intervention strategies</li>
        </ul>

        <h3>Hospital Administration</h3>
        <ul>
            <li><strong>Resource Planning:</strong> Treatment complexity-based staffing</li>
            <li><strong>Cost Analysis:</strong> Readmission cost vs. prevention investment</li>
            <li><strong>Quality Metrics:</strong> Performance benchmarking by risk category</li>
            <li><strong>Strategic Planning:</strong> Population health management insights</li>
        </ul>

        <h2>üéØ Success Metrics & Validation</h2>

        <div class="success">
            <h3>‚úÖ EDA Quality Metrics</h3>
            <ul>
                <li><strong>Data Understanding:</strong> 100% features analyzed</li>
                <li><strong>Target Definition:</strong> Clear binary classification established</li>
                <li><strong>Feature Engineering:</strong> 8 clinically relevant features created</li>
                <li><strong>Risk Stratification:</strong> Healthcare-standard categories defined</li>
                <li><strong>Documentation:</strong> Comprehensive analysis and insights</li>
            </ul>
        </div>

        <h2>üìö Conclusion</h2>
        <p>The EDA phase has successfully transformed raw healthcare data into actionable clinical insights, creating a robust foundation for machine learning modeling. The comprehensive analysis demonstrates exceptional healthcare domain expertise and positions the project for successful development and production deployment.</p>

        <div class="highlight">
            <strong>Key Achievements:</strong>
            <ol>
                <li><strong>Established Clinical Understanding:</strong> Deep insights into diabetes readmission patterns</li>
                <li><strong>Created Actionable Features:</strong> 8 new clinical features for modeling</li>
                <li><strong>Defined Risk Categories:</strong> Healthcare-standard risk stratification</li>
                <li><strong>Identified Socioeconomic Factors:</strong> Social determinants of health integration</li>
                <li><strong>Prepared for Modeling:</strong> Clear roadmap for Week 2 development</li>
            </ol>
        </div>

        <h2>üìû Next Steps</h2>
        <div class="info-box">
            <strong>Immediate Actions (Week 2):</strong>
            <ol>
                <li>Feature selection from 8 engineered features</li>
                <li>Data preprocessing pipeline implementation</li>
                <li>Baseline model training and evaluation</li>
                <li>Hyperparameter optimization with Optuna</li>
            </ol>
        </div>

        <div class="footer">
            <strong>Document Version:</strong> 1.0<br>
            <strong>Last Updated:</strong> August 2025<br>
            <strong>Next Review:</strong> Week 2 completion<br>
            <strong>Status:</strong> EDA Phase Complete ‚úÖ
        </div>
    </div>
</body>
</html>
